Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: roger m who wrote (8123)	12/25/1998 12:15:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

As you say>" It doesn't seem like a blockbuster drug"....................>> >>>>That says it all IMO. Also xoma did invest 500,000+ to do the Bermuda thing. I hope it turns out to be money well spent. Rightly or wrongly I just voted for Bermuda. Merry Christmas and Happy holidays.

To: roger m who wrote (8123)	12/26/1998 7:40:00 PM
From: Tharos	Read Replies (2) \| Respond to of 17367

Yes, this is a high-risk investment. Invest/speculate accordingly. Yes, the meningitis market is a small one. But this ignores some considerable potential: - hu1124 looks like it can help/cure psoriasis, current next best treatment is mud from the Dead Sea (no kidding). - Neuprex has shown itself to have antibiotic synergy, meaning it holds the potential to make current ineffective and moderately effective antibiotics effective once again. Antibiotic resistance is a current reality and a looming plague. - Neuprex is showing itself to be effective in treating blunt trauma induced infections. - Neuprex may finally be the sepsis drug being sought after by many. Huge market here. $500 million to $2 billion, depending on which article you read. - There are literally hundreds of clinical studies done with BPI, and just as many articles about BPI. Three or four of these suggest it is doubtful BPI (Neuprex is rBPI) works. The rest suggest it does.